Monitoring blood markers in elderly patients with acute leukemia after chemotherapy
Official title: Monitoring Circulating Tumor DNA After Chemotherapy in Elderly Patients With Acute Leukemia
Run by Navy General Hospital, Beijing · NCT04157569 · Data updated 2026-11-12
This study is testing if measuring certain blood markers can help doctors understand how well chemotherapy is working for older patients with acute leukemia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 60 Years to 100 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Navy General Hospital, Beijing Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | November 5, 2019 |
| Main results expected | December 31, 2024 |
| Study ends | December 31, 2029 |
| Registry record updated | February 25, 2020 |
| Trial ID | NCT04157569 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are elderly male patients aged 60 years and older who have been diagnosed with acute leukemia.
✕Probably not a fit
Patients who are pregnant, HIV positive, or aged 100 years and older may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to monitor circulating tumor DNA (CtDNA) levels in elderly patients diagnosed with acute leukemia following chemotherapy treatment. Utilizing the droplet digital PCR (ddPCR) method, the study will quantify the mutant allele frequency (MAF) in peripheral blood plasma to assess the clinical significance of CtDNA in this patient population. The findings may provide insights into treatment efficacy and disease progression in elderly patients.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of treatment responses in elderly acute leukemia patients, potentially leading to improved monitoring and management strategies.
How similar studies have gone: While the use of CtDNA monitoring in cancer treatment is gaining traction, this specific approach in elderly acute leukemia patients is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Written informed consent * Male * not pregnant female * patients \>=60 years old * Diagnosis of acute leukemia Exclusion Criteria: * Pregnancy * HIV positive * patients \>=100 years old
Where it's running
-
Navy General Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Liren Qian, MD
- Email: qlr2007@126.com
- Phone: +861066957676
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Menin inhibitors in pediatric relapsed or refractory acute leukemia
This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.
-
Artistic and movement activities to help anxiety in kids with ALL
Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.
-
Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma
Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.
-
QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers
This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.
-
Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers
This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.
-
Menin inhibitor maintenance after allogeneic stem cell transplant
This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.